KLK3 and prostate cancer: While insured patients are more likely to have a primary care provider (PCP), studies report that the USPSTF’s screening recommendation led to a 39% decrease in PSA testing by PCPs along with 62.3% of PCPs being less likely to screen or cease screening altogether, thereby partially negating the protective effect of having a PCP in managing prostate cancer [21–24].